Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Gating properties of SCN5A mutations and the response to mexiletine in long-QT syndrome type 3 patients.

Circulation - 4 Sept 2007

Ruan Yanfei, Liu Nian, Bloise Raffaella, Napolitano Carlo, Priori Silvia G

Abstract excerpt

BACKGROUND: Mexiletine (Mex) has been proposed as a gene-specific therapy for patients with long-QT syndrome type 3 (LQT3) caused by mutations in the cardiac sodium channel gene (SCN5A). The degree of QT shortening and the protection from arrhythmias vary among patients harboring different mutations. We tested whether the clinical response to Mex in LQT3 could be predicted by the biophysical properties of the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Child, Preschool
Share to Genetic Therapy
Share to Infant

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Ion Channel Gating

Share to Long QT Syndrome

Share to Muscle Proteins

Share to NAV1.5 Voltage-Gated Sodium Channel

Share to Sodium Channels

Source

Identifiers

PMID: 17698727
DOI: 10.1161/CIRCULATIONAHA.107.707877

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Gating properties of SCN5A mutations and the response to mexiletine in long-QT syndrome type 3 patients.PMID 17698727Read ↗

Trafficking defects and gating abnormalities of a novel SCN5A mutation question gene-specific therapy in long QT syndrome type 3.Semantic proximity Read ↗

Mexiletine rescues a mixed biophysical phenotype of the cardiac sodium channel arising from the SCN5A mutation, N406K, found in LQT3 patients.Semantic proximity Read ↗

Complex interactions in a novel SCN5A compound mutation associated with long QT and Brugada syndrome: Implications for Na+ channel blocking pharmacotherapy for de novo conduction disease.Semantic proximity Read ↗

A novel and lethal de novo LQT-3 mutation in a newborn with distinct molecular pharmacology and therapeutic response.Semantic proximity Read ↗

Long QT syndrome patients with mutations of the SCN5A and HERG genes have differential responses to Na+ channel blockade and to increases in heart rate. Implications for gene-specific therapy.Semantic proximity Read ↗

The E1784K mutation in SCN5A is associated with mixed clinical phenotype of type 3 long QT syndrome.Semantic proximity Read ↗

A novel SCN5A arrhythmia mutation, M1766L, with expression defect rescued by mexiletineSemantic proximity Read ↗

Common Genetic Variants of The Cardiac Sodium Channel Alter Patient Response to Class 1b AntiarrhythmicsSemantic proximity Read ↗

Mechanisms by which SCN5A mutation N1325S causes cardiac arrhythmias and sudden death in vivo.Semantic proximity Read ↗

Human iPS cell model of type 3 long QT syndrome recapitulates drug-based phenotype correction.Semantic proximity Read ↗

A trafficking defective, Brugada syndrome-causing SCN5A mutation rescued by drugsSemantic proximity Read ↗

Reduced current density, partially rescued by mexiletine, and depolarizing shift in activation of SCN5A W374G channels as a cause of severe form of Brugada syndrome.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.